{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:17:19Z","timestamp":1777378639198,"version":"3.51.4"},"reference-count":0,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:p>COL40263 was a pilot 48-week, open-label, multicenter study evaluating the efficacy and safety of once-daily coformulated abacavir\/lamivudine\/zidovudine plus tenofovir in ART-naive, HIV-infected subjects. We examined the patterns of resistance that were selected on-therapy through 48 weeks in subjects with virologic nonresponse (VF). A total of 123 antiretroviral-naive HIV-1-infected subjects with plasma HIV-1 RNA \u226530,000copies\/ml were enrolled. For subjects with confirmed VF (HIV-1 RNA \u2265400\u2009copies\/ml at week 24 or later), HIV population genotypic and phenotypic analysis was performed. Of the 123 enrolled subjects, 14 (11%) had confirmed plasma HIV-1 RNA \u2265400\u2009copies\/ml through week 48. Of these subjects, 3\/14 had evidence of drug resistance at baseline: 2\/14 had HIV with K103N, Y188F\/H\/L\/Y, and\/or T215A and 1\/14 had reduced zidovudine susceptibility. At the last time point analyzed, 4\/14 subjects had wild-type HIV, while 10\/14 subjects had HIV with either thymidine analogue mutations (TAMS) alone (3\/10), TAMS\u2009+\u2009M184V (4\/10), M184V only (1\/10), or K65R\/K (2\/10). Matched phenotype was obtained for 13\/14 subjects and 8\/13 (62%) subjects had reduced susceptibility to one or more study drugs: 2\/13 tenofovir, 3\/13 abacavir, 4\/13 zidovudine, and 7\/13 lamivudine. The resistance pattern in COL40263 subjects with VF differs significantly from that reported for tenofovir-containing triple-nucleoside regimens. TAMs were detected in the majority (7\/10) of samples from subjects with VF who selected any resistance mutation. These data suggest that TAMs selection is a preferred resistance route of this combination, with zidovudine modulating the resistance pathway against selection for K65R.<\/jats:p>","DOI":"10.1089\/aid.2008.0302","type":"journal-article","created":{"date-parts":[[2009,6,29]],"date-time":"2009-06-29T08:41:31Z","timestamp":1246264891000},"page":"665-672","source":"Crossref","is-referenced-by-count":8,"title":["Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection in Subjects with Virologic Failure Receiving Once-Daily Abacavir\/Lamivudine\/Zidovudine and Tenofovir DF (Study COL40263)"],"prefix":"10.1177","volume":"25","author":[{"given":"Lisa","family":"Ross","sequence":"first","affiliation":[{"name":"GlaxoSmithKline"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Elion","sequence":"additional","affiliation":[{"name":"George Washington School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Lanier","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"Dejesus","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin","family":"Cohen","sequence":"additional","affiliation":[{"name":"Community Research Initiative"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Redfield","sequence":"additional","affiliation":[{"name":"University of Maryland Institute of Human Virology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Gathe","sequence":"additional","affiliation":[{"name":"Therapeutic Concepts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricky K.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Saint Vincent's Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Yau","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Paulsen","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Ha","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,7,1]]},"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2008.0302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2008.0302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:11:48Z","timestamp":1777367508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/aid.2008.0302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1089\/aid.2008.0302"],"URL":"https:\/\/doi.org\/10.1089\/aid.2008.0302","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}